Related Experiment Video
Updated: May 19, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[B-cell-directed therapy in patients with connective tissue diseases]
1Sektion Rheumatologie und Klinische Immunologie/ Innere Medizin D, Universitätsklinikum Münster. annett.jacobi@ukmuenster.de
Deutsche Medizinische Wochenschrift (1946)
|August 31, 2012
Summary
B cell therapies offer new treatment options for autoimmune diseases like SLE. Further research is needed to address unmet needs and ensure the safety and efficacy of these targeted treatments.
Area of Science:
- Immunology
- Autoimmunity
- Therapeutics
Context:
- B cells play a crucial role in autoimmune diseases by presenting antigens, secreting cytokines, and differentiating into antibody-producing cells.
- Autoantibody-mediated autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and other connective tissue diseases, represent a significant therapeutic challenge.
- Current treatment strategies are exploring B cell-directed therapies to manage these conditions.
Purpose:
- To review the benefits and limitations of B cell-targeting therapies in autoimmune diseases.
- To identify and discuss the unmet medical needs in the context of B cell-directed treatments.
- To highlight the importance of further research and data collection for refractory patients.
Summary:
- B cells are key players in autoimmune diseases, making them a prime target for novel therapies.
- B cell-directed treatments are expanding therapeutic options for conditions like SLE, but challenges remain.
- Addressing unmet medical needs requires continued investigation into the efficacy and safety of these emerging treatments.
Impact:
- B cell targeting broadens the therapeutic armamentarium for SLE and other connective tissue diseases.
- Further research is essential to optimize B cell-directed therapies and address patient populations with unmet needs.
- Establishing patient registries for those receiving off-label B cell therapeutics is crucial for gathering real-world data on value and safety.
Related Concept Videos
01:22Connective Tissue Cell Types
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...